RG 7880Alternative Names: IL22-Fc; RG7880; RO 7021610; UTTR1147A
Latest Information Update: 19 Jul 2016
At a glance
- Originator Roche
- Developer Genentech
- Mechanism of Action Interleukin-22 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Diabetic foot ulcer; Ulcerative colitis
Most Recent Events
- 01 May 2016 Phase-I clinical trials in Diabetic foot ulcer (Treatment-experienced) in Spain (SC) (NCT02833389)
- 01 Apr 2016 Phase-I clinical trials in Ulcerative colitis in Germany (IV) (NCT02749630)